Project cooperationUpdated on 9 April 2026
Investment Opportunities
About
-
20/20 OptimEyes Technologies – sustained-release drug delivery for veterinary ophthalmology and mucosal indications
-
Saccharide Therapeutics – synthetic glycoconjugate vaccine for malaria
-
Fina Biosolutions – revenue-generating platforms enabling cost-effective conjugate vaccine development with high-quality, affordable CRM197
-
ENABLE Biotech - a next-generation CDMO based in Switzerland, specializing in the development and early-stage clinical manufacturing of cell and exosome therapies
Stage
- Execution
Topic
- Biotech, Pharma and Cosmetics
Type
- Coordinator looking for partners
Organisation
Similar opportunities
Project cooperation
Portfolio Company Collaboration: 20/20 OptimEyes Technologies
- Research
- Execution
- Technical
- Biotech, Pharma and Cosmetics
Renaud Jacquemart
CEO at Omnium Global
Burlington, Canada
Project cooperation
Portfolio Company Collaboration: Fina Biosolutions
- Planning
- Research
- Execution
- Technical
- Environment
- Biotech, Pharma and Cosmetics
- Food, Beverages and Agriculture
Renaud Jacquemart
CEO at Omnium Global
Burlington, Canada
Expertise
- Healthcare
- Biotech, Pharma and Cosmetics
- Food, Beverages and Agriculture
Sonia Thomson
Communication specialist at Biotechnet Switzerland
Muttenz, Switzerland